Please login to the form below

migraine

This page shows the latest migraine news and features for those working in and with pharma, biotech and healthcare.

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline. Denmark’s Lundbeck has made another foray into M&A, buying Alder BioPharma and its late-stage migraine drug eptinezumab for $1.95bn. ... The deal also gives it a follow-up drug for migraine prevention – PACAP

Latest news

AbbVie/Allergan's merger faces public opposition

Allergan’s biggest product, Botox, is also facing tougher competition in the market from new migraine drugs and rivals in its medical aesthetics indications.
Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

also have documented previous failures on two to four different migraine preventative medications. ... self-reported failures on various migraine preventative medications prior to enrolment in the study.
Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Not all have stayed the distance though – Teva was another partner on a $410m migraine project but ducked out last year and returned rights to the biotech.
Amazon’s Alexa to provide NHS health information

a migraine?” and similar queries about symptoms of flu and chickenpox.
New efficacy data boosts Aimovig’s migraine market lead

Data should help boost uptake. Novartis has presented new data showing Aimovig cuts acute migraine medication days by half in patients who have failed prior preventive therapies. ... Other contenders in the class are Eli Lilly’s Emgality and Teva’s

More from news
Approximately 24 fully matching, plus 138 partially matching documents found.

Latest Intelligence

Key considerations for disease- modifying Parkinson’s disease trials

Published adherence in migraine-prophylaxis (as a comparable indication) indicates 92.6% adherent at one month, 40.7% at two months, 30.9% at three months, 24.8% at four months,
Deal Watch January 2018

Teva’s CGRP patent portfolio to develop, manufacture and commercialise eptinezumab, its phase III CGRP antibody for the treatment of migraine. In exchange for the licence, Alder will withdraw its appeal
The good, the bad and the ugly

Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.
The cultural construction of illness

Some years ago, we were asked to advise on marketing a cure for migraines in the UK. ... In this world, migraines were associated with ideas of the overly sensitive, or even hysterical woman, requiring rational male intervention to bring her back to her
Ditch the data?

Around one in seven people suffer from migraines, and these can impact severely on quality-of-life. ... When a migraine hits, she needs to shut herself in a dark room in silence.

More from intelligence
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest appointments

Newron Pharma appoints commercial affairs VP

He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis.
Red Door Unlimited appoints new digital strategy head

Prior to joining the agency, Morgan worked on accounts in patient advocacy for cancer immunotherapy, hepatitis C treatments and migraines for Firstlight PR and Hill and Knowlton Strategies.
Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

operations. This includes ensuring the success of current products, such as Sumavel DosePro for migraine, as well as soon to be launched products, such as Zohydro, which is pending FDA approval

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Research Partnership has published a new Living with Chronic Pain market report for 2016

Living with Chronic Pain is a quantitative study conducted online amongst 390 US patients with diabetic neuropathic pain, chronic lower back pain, cancer pain and headache/migraine pain.
What it takes to win at Cannes Health Lions

As for Martin, DDB Remedy won a Silver and Two bronze awards for an integrated campaign for Excedrin, an OTC migraine treatment in the US, helping to address the issue that ... people often respond to someone with a migraine by just saying that it’s
Double Communiqué award win for 90TEN

The Migraine Unlocked campaign took a surround-sound communications approach using advertising, media and grassroots campaigning to maximise exposure to sufferers and their loved ones. ... Commenting on Migraine Unlocked, t he Comm uniqué judges said:
90TEN nominated for five Communique Awards including Small Consultancy of the Year

The Allergan “Migraine Unlocked” campaign is a finalist in Excellence in Communications via a Live Event or Stand-Alone Activity, and an HCV programme for AbbVie has been recognised in the